
Opinion|Videos|July 30, 2024
Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC
Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?
Advertisement
Related to this article

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.

Mohit Khera, MD, MBA, MPH, discusses preliminary research on radiofrequency therapy as a potential treatment for vasculogenic erectile dysfunction.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
3
Treatment Targets, Formulations, and the Future of Testosterone
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5

